Restructuring announcements and plans to lay off significant numbers of employees unfortunately have become the norm rather than the exception in 2022 as biopharmaceutical company stock prices sink and firms look for ways to conserve cash on hand.
For Sio Gene Therapies, Inc., the latest strategic shift could spell the end of a company that already has changed directions many times before. Genocea Biosciences, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?